Skip to content

​Hememics’ graphene-based platform validated by KanPro Research, securing commercial trial order 

​Hememics’ graphene-based platform validated by KanPro Research, securing commercial trial order 

Hememics Biotechnologies, developer of graphene-based biosensing technology, has announced the successful on-site demonstration of its ESAP™ (Electrostatic Sensing for Analyte Profiling) platform at KanPro Research, Inc., a premier protein science and biomanufacturing CRO founded by Dr. Philip Gao.

Following a successful initial blind study that established proof-of-concept, and a subsequent on-site demonstration confirming the ability of ESAP™ to deliver definitive antibody-antigen binding results in under one hour-using a low-cost, disposable graphene chip cartridge-KanPro Research has reportedly placed an immediate commercial trial order to integrate ESAP™ into its production and validation workflows.

 ​

Hememics Biotechnologies, developer of graphene-based biosensing technology, has announced the successful on-site demonstration of its ESAP™ (Electrostatic Sensing for Analyte Profiling) platform at KanPro Research, Inc., a premier protein science and biomanufacturing CRO founded by Dr. Philip Gao.Following a successful initial blind study that established proof-of-concept, and a subsequent on-site demonstration confirming the ability of ESAP™ to deliver definitive antibody-antigen binding results in under one hour-using a low-cost, disposable graphene chip cartridge-KanPro Research has reportedly placed an immediate commercial trial order to integrate ESAP™ into its production and validation workflows. 

Read More Graphene-Info – Graphene industry portal